Fairuz Zein, known professionally as Fay Zein, serves as a Senior Investment Consultant at Bios Health Group, where she leverages her extensive background in biotechnology and venture capital to drive strategic investments in life sciences. With a robust foundation in both biology and business, Fay...
Fairuz Zein, known professionally as Fay Zein, serves as a Senior Investment Consultant at Bios Health Group, where she leverages her extensive background in biotechnology and venture capital to drive strategic investments in life sciences. With a robust foundation in both biology and business, Fay combines her MBA and thesis-based Master of Science in Structural Biology to identify and nurture seed-stage startups while providing critical investment advisory services to late-stage biopharma companies. Her unique blend of expertise in finance, mRNA engineering, and oncology positions her as a key player in shaping the future of health innovation.
At Bios Health Group, Fay is currently spearheading several key projects that focus on advancing cutting-edge therapies and technologies. Her role involves conducting thorough due diligence and financial modeling to assess the viability of emerging biotech ventures. Fay's commitment to Kaizen Leadership principles ensures that she fosters a culture of continuous improvement within her team, enhancing the decision-making process and optimizing investment strategies. Her hands-on experience in laboratory research and development, particularly in the fields of antibodies and oncology, allows her to evaluate scientific merit alongside financial potential, ensuring that investments align with both market needs and scientific advancements.
Fay Zein's passion for biotechnology and her strategic insights into the investment landscape make her an invaluable asset to Bios Health Group. Her ability to navigate the complexities of the biotech industry, coupled with her dedication to supporting innovative startups, positions her at the forefront of transformative health solutions that have the potential to improve patient outcomes globally.
